

Synthesis and Characterization of Imidazo[1,2-a]pyridines and Zolimidine

NARVA DESHWAR KUSHWAHA^{1,2,*}, SOMNATH MONDAL¹, RENU SHARMA² and NARESH KUMAR¹

¹Jubilant Chemsys Ltd., B-34, Sector-58, Noida-201 301, India

²NIMS University, Shobha Nagar, Jaipur-303 121, India

*Corresponding author: E-mail: narvadeshwarkushwaha@gmail.com

Received: 23 January 2017;

Accepted: 9 March 2017;

Published online: 13 May 2017;

AJC-18381

A convenient and efficient synthesis, without any organic solvent or catalyst is described for the preparation of imidazo[1,2-a]pyridine derivatives. The reaction has been done between 2-aminopyridines and α -bromoacetone derivatives in good to excellent yields in water. In several cases the isolation does not require any chromatography for purification. The reaction thus developed has been applied for quick synthesis of zolimidine with 91 % yield.

Keywords: Imidazo[1,2-a]pyridine, 2-Aminopyridines, α -Bromoacetone, Zolimidine.

INTRODUCTION


Organic chemists are continuously searching for the chemical reaction in non-hazardous conditions to minimize the generation of hazardous substances in the environment [1]. Water is the ideal solvent for chemical reaction as it is safe and environmental friendly [1,2]. But, in general, its use is limited in chemical reactions because most of the organic compounds are either insoluble or unstable [3]. Herein we report synthesis of imidazo[1,2-a]pyridine derivatives in water with high yields.

Imidazo[1,2-a]pyridine derivatives are an important class of molecules and have wide variety of biological activities such as anti-inflammatory, antiviral, antibacterial, antifungal, antiprotozoal, immunomodulatory, gastrointestinal, anxiolytic, hypnotic and antiulcer activities [4,5].

Imidazo[1,2-a]pyridine moieties also known in certain drug molecules such as zolpidem (**I**, treatment of insomnia), alpidem (**II**, an anxiolytic agent), minodronic acid (**III**, use for osteoporosis treatment) and zolimidine (**IV**, for peptic ulcer treatment) [6] (Fig. 1).

Three component coupling reaction are available using 2-amino pyridines, aldehyde/alkyl halide and alkynes/isocyanide [7,8]. Adib *et al.* [3] reports such reaction in a catalyst-free reaction in water at 70 °C.

Two component systems are also done with condensation of 2-aminopyridine with α -haloketones [4,5,9]. Most of the reactions uses polar organic solvent (particularly ethanol or methanol) in presence/absence of different bases (Scheme-I). The isolation and purification has been done by using column chromatography to obtained moderate to good yields [4,5,10].



Scheme-I: Preparation of imidazo-pyridines in ethanol

Syntheses have also been carried out under microwave irradiation in the presence of Montmorillonite K10 [11], Sc(OTf)₃ [12], *etc.* It has also been performed using a non-polar solvent [13], or in the presence of an ionic liquid [14].




Fig. 1. Few examples of imidazo[1,2-a]pyridine containing drugs


In recent years several improved conditions have been reported [15]. Lei *et al.* [16] published the results on synthesis of imidazo[1,2-*a*]pyridines using silver carbonate in dioxane at 110 °C, with moderate yields [16] and Cai *et al.* [17] reported synthesis of imidazo[1,2-*a*]pyridines using I_2/CuO in methanol. Though these methods are useful, but use of water as solvent for organic reactions is the most interesting and attracted step because of its economic and environmental friendly nature.

EXPERIMENTAL

Unless otherwise noted all reactions were carried out at room temperature. Solvents and reagents were purchased at the highest commercial quality and used without further drying and purification respectively. Reactions were monitored by thin-layer chromatography (TLC) analysis using TLC aluminum sheets silica gel 60 F254.

1H NMR and ^{13}C NMR spectra were recorded in $CDCl_3$ and $DMSO-d_6$ at 400 MHz. The chemical shifts are reported in ppm downfield to TMS ($\delta = 0$) for 1H NMR and ^{13}C NMR. The water was prepared from tap water after sand filter-carbon filter-ionic exchange resin-reverse osmosis-UV-micro filter by passing through pre-packed cartridges.


General procedure and representative analytical data of imidazo[1,2-*a*]pyridines: A solution of 2-aminopyridine (1 eq) and α -bromoketone (1 eq) in water was stirred at room temperature for 8 h (Scheme-II). For some insoluble 2-aminopyridine, it was dissolved by heating up to 60-70 °C and then added α -bromoketones. The reactions were performed at room temperature for 8 h (Scheme-III). After completion of the reaction, the reaction mixture was basified (pH = 9) with 10 % NaOH aqueous solution. In many cases product was precipitated out, so it was filtered to get pure compound. If product was not solid, it was extracted with pentane to get product in pure form.



R = H, Me, Cl R₁ = Et, t-Bu, Ph, Cyclohexyl

Scheme-II

Synthesis of zolimidine: The suspension of 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (1 eq) and pyridin-2-amine (3 eq) in water was stirred at room temperature for 18 h (Scheme-IV). The heterogeneous reaction mixture was directly filtered and washed with water, followed by diethyl ether to get yellow solid zolimidine (91 %).



R = 4-bromo, 3-cyano, 3-chloro, 5-chloro, 5-bromo

Scheme-III: Reaction of different substituted 2 amino pyridine and 1-bromo-3,3-dimethylbutan-2-one

2-(*tert*-Butyl)imidazo[1,2-*a*]pyridine (3a): m.p.: 81-82 °C (80 °C) [1]; 1H NMR (400 MHz, $DMSO-d_6$): δ 8.51 (d, $J = 6.8$ Hz, 1H), 7.77 (s, 1H), 7.55 (d, $J = 9.2$ Hz, 1H), 7.34-7.30 (m, 1H), 6.96-6.93 (m, 1H), 1.33 (s, 9H). MS, m/z : 175.04 ($M+H^+$).

2-(*tert*-Butyl)-7-methylimidazo[1,2-*a*]pyridine (3b): m.p.: 94-96 °C (lit. 96-98 °C) [2]. 1H NMR (400 MHz, $CDCl_3$): δ 7.90 (d, $J = 6.8$ Hz, 1H), 7.32 (s, 1H), 7.24 (s, 1H), 6.53 (d, $J = 6.8$ Hz, 1H), 2.35 (s, 3H), 1.38 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 156.97, 145.46, 134.59, 124.60, 115.64, 114.16, 106.04, 32.22, 30.22, 21.32. MS, m/z : 189.13 ($M+H^+$).

2-(*tert*-Butyl)-7-chloroimidazo[1,2-*a*]pyridine (3c): m.p.: 136-138 °C; 1H NMR (400 MHz, $CDCl_3$): δ 7.95 (d, $J = 7.2$ Hz, 1H), 7.56 (s, 1H), 7.31 (s, 1H), 6.70 (dd, $J = 6.8$ Hz, $J = 1.6$ Hz, 1H), 1.38 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 158.36, 144.78, 130.17, 125.58, 116.12, 113.23, 106.95, 32.35, 30.11. MS, m/z : 209.0 ($M+H^+$).

2-Ethylimidazo[1,2-*a*]pyridine (3d): 1H NMR (400 MHz, $CDCl_3$): δ 8.03 (d, $J = 6.8$ Hz, 1H), 7.52 (d, $J = 9.2$ Hz, 1H), 7.33 (s, 1H), 7.12-7.08 (m, 1H), 6.73-6.71 (m, 1H), 2.82 (q, $J = 7.6$ Hz, 2H), 1.34 (t, $J = 7.6$ Hz, 3H). MS, m/z : 146.99 ($M+H^+$).

2-Ethyl-7-methylimidazo[1,2-*a*]pyridine (3e): 1H NMR (400 MHz, $CDCl_3$): δ 7.90 (d, $J = 6.8$ Hz, 1H), 7.25 (d, $J = 8.0$ Hz, 2H), 6.54 (d, $J = 6.8$ Hz, 1H), 2.79 (q, $J = 7.6$ Hz, 2H), 2.36 (s, 3H), 1.33 (t, $J = 7.6$ Hz, 3H). MS, m/z : 161.07 ($M+H^+$).

7-Chloro-2-ethylimidazo[1,2-*a*]pyridine (3f): 1H NMR (400 MHz, $CDCl_3$): δ 7.95 (d, $J = 7.2$ Hz, 1H), 7.51 (s, 1H), 7.31 (s, 1H), 6.71 (dd, $J = 7.2$ Hz, $J = 2.0$ Hz, 1H), 2.80 (q, $J = 7.6$ Hz, 2H), 1.33 (t, $J = 7.6$ Hz, 3H). MS, m/z : 181.09 ($M+H^+$).

2-Cyclohexylimidazo[1,2-*a*]pyridine (3g): 1H NMR (400 MHz, $DMSO-d_6$): δ 8.43 (d, $J = 6.8$ Hz, 1H), 7.64 (s, 1H), 7.43 (d, $J = 8.8$ Hz, 1H), 7.16-7.12 (m, 1H), 6.81-6.78 (m, 1H), 2.65 (bs, 1H), 2.02-1.99 (m, 2H), 1.78-1.67 (m, 3H), 1.58-1.32 (m, 4H), 1.27-1.23 (m, 1H). MS, m/z : 201.20 ($M+H^+$).

2-Cyclohexyl-7-methylimidazo[1,2-*a*]pyridine (3h): 1H NMR (400 MHz, $DMSO-d_6$): δ 8.30 (d, $J = 6.8$ Hz, 1H), 7.53 (s, 1H), 7.20 (s, 1H), 6.64 (d, $J = 6.8$ Hz, 1H), 2.61 (bs, 1H), 2.31 (s, 3H), 2.06-2.01 (m, 2H), 1.77-1.61 (m, 3H), 1.45-1.31 (m, 4H), 1.08-1.00 (m, 1H). MS, m/z : 215.21 ($M+H^+$).

7-Chloro-2-cyclohexylimidazo[1,2-*a*]pyridine (3i): 1H NMR (400 MHz, $CDCl_3$): δ 7.95 (d, $J = 7.2$ Hz, 1H), 7.52 (s, 1H), 7.28 (s, 1H), 6.71 (d, $J = 7.2$ Hz, 1H), 2.74-2.72 (m, 1H), 2.12-2.09 (m, 2H), 1.85-1.82 (m, 2H), 1.76-1.30 (m, 1H), 1.52-1.37 (m, 4H), 1.35-1.26 (m, 1H). MS, m/z : 235.11 ($M+H^+$).

2-Phenylimidazo[1,2-*a*]pyridine (3j): 1H NMR (400 MHz, $CDCl_3$): δ 8.13 (d, $J = 6.8$ Hz, 1H), 7.98-7.96 (m, 2H), 7.87 (s, 1H), 7.64 (d, $J = 9.2$ Hz, 1H), 7.46-7.42 (m, 2H), 7.35-7.31 (m, 1H), 7.19-7.15 (m, 1H), 6.80-6.77 (m, 1H). MS, m/z : 195.00 ($M+H^+$).

7-Methyl-2-phenylimidazo[1,2-*a*]pyridine (3k): 1H NMR (400 MHz, $CDCl_3$): δ 7.99 (d, $J = 6.8$ Hz, 1H), 7.93 (d, $J = 7.6$ Hz, 2H), 7.78 (s, 1H), 7.44-7.30 (m, 3H), 7.26 (s, 1H), 6.6 (d, $J = 6.8$ Hz, 1H), 2.39 (s, 3H). MS, m/z : 209.08 ($M+H^+$).

7-Chloro-2-phenylimidazo[1,2-*a*]pyridine (3l): 1H NMR (400 MHz, $CDCl_3$): δ 8.05 (d, $J = 7.2$ Hz, 1H), 7.93 (d,

$J = 7.2$ Hz, 2H), 7.84 (s, 1H), 7.64 (s, 1H), 7.46-7.42 (m, 2H), 7.36-7.33 (m, 1H), 6.78 (d, $J = 5.2$ Hz, 1H). MS, m/z : 229.04 ($M+H^+$).

7-Bromo-2-(*tert*-butyl)imidazo[1,2-a]pyridine (6a): ^1H NMR (400 MHz, CDCl_3): δ 7.90 (d, $J = 7.2$ Hz, 1H), 7.75 (s, 1H), 7.31 (s, 1H), 6.81 (dd, $J = 7.2$ Hz, $J = 1.6$ Hz, 1H), 1.38 (s, 9H). MS, m/z : 253.02 ($M+H^+$).

2-(*tert*-Butyl)imidazo[1,2-a]pyridine-8-carbonitrile (6b): ^1H NMR (400 MHz, CDCl_3): δ 8.23 (d, $J = 7.2$ Hz, 1H), 7.55 (d, $J = 7.2$ Hz, 1H), 7.45 (s, 1H), 6.80-6.76 (m, 1H), 1.41 (s, 9H). MS, m/z : 200.06 ($M+H^+$).

2-(*tert*-Butyl)-8-chloroimidazo[1,2-a]pyridine (6c): ^1H NMR (400 MHz, CDCl_3): δ 7.97 (d, $J = 6.4$ Hz, 1H), 7.39 (s, 1H), 7.17 (d, $J = 7.2$ Hz, 1H), 6.66-6.62 (m, 1H), 1.41 (s, 9H). MS, m/z : 209.04 ($M+H^+$).

2-(*tert*-Butyl)-6-chloroimidazo[1,2-a]pyridine (6d): ^1H NMR (400 MHz, CDCl_3): δ 8.08 (s, 1H), 7.50 (d, $J = 8.8$ Hz, 1H), 7.31 (s, 1H), 7.07 (dd, $J = 9.6$ Hz, $J = 1.6$ Hz, 1H), 1.39 (s, 9H). MS, m/z : 209.06 ($M+H^+$).

6-Bromo-2-(*tert*-butyl)imidazo[1,2-a]pyridine (6e): ^1H NMR (400 MHz, CDCl_3): δ 8.18 (s, 1H), 7.46 (d, $J = 9.6$ Hz, 1H), 7.31 (s, 1H), 7.16 (d, $J = 9.6$ Hz, 1H), 1.39 (s, 9H). MS, m/z : 254.95 ($M+H^+$).

2-[4-(Methylsulfonyl)phenyl]imidazo[1,2-a]pyridine (IV): m.p.: 222-224 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.15 (d, $J = 8.8$ Hz, 3H), 8.09 (d, $J = 9.6$ Hz, 3H), 7.65 (d, $J = 9.2$ Hz, 1H), 7.22 (d, $J = 8.4$ Hz, 1H), 6.84 (t, $J = 6.8$ Hz, 1H), 3.09 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 145.98, 143.57, 139.27, 127.92, 126.61, 125.86, 125.56, 117.86, 113.10, 109.69, 44.63. MS, m/z : 273.15 ($M+H^+$).

RESULTS AND DISCUSSION

While pursuing synthesis of some specific imidazo[1,2-a]pyridines, we hypothesized this to be ideal reaction for trying in water as solvent. This has been further developed as reaction without use of any base/catalyst and isolating without any chromatography. The reaction produces good to excellent isolated yields at room temperature (Table-1). Three amino


pyridines: no substitution, 4-methyl and 4-chloro have been selected to represent variety. These are made to react with α -bromoacyl derivatives with bulky group *t*-butyl, ethyl, cyclohexyl and phenyl. All the 12 products are obtained in good to excellent yields (64-91 %).

The isolation of the product needs basification of the reaction mixture with aq. sodium hydroxide to precipitate out required compounds or to extract the compounds in pentane.

Some of the substituted 2-amino pyridines (**Scheme-III**) showed insolubility in water, so were warmed up to 60-70 °C for making a clear solution. The reaction proceeded at room temperature and produced the required product in good yields (72-80 %), except for **6b** (40 %). We believe the steric may not be the reason for such low yields. As the 3-chloro amino pyridine gave good yield (80 %), so the poor yield may be due to complication by participation of CN group during product formation (Table-2). All the compounds are purified without column chromatography.

The water plays a role of reaction medium only and does not play any role in the reaction mechanism. This was evident by performing a reaction in heavy water (example **3b**). The reaction gave similar high yield as in water (91 % vs. 88 %). This result is in contrast to the results obtained in literature [18]. The NMR data of the product **3b** obtained in heavy water was same as the one obtained in water.

The developed reaction was applied to synthesize the zolimidine (**IV**) as per **Scheme-IV**. It gave the required product in good yields (91 %) and high purity (> 97 %) and was isolated with simple filtration. In recent paper, it has been synthesized over two steps (overall yield 40 %) [16]. The high yields and quick isolation makes it ideal route for scale up and manufacturing of zolimidine.



Scheme-IV: Synthesis of zolimidine in water

TABLE-1
YIELD OF IMIDAZO[1,2-a]PYRIDINES FROM 2-AMINO PYRIDINE AND α -BROMOACETONE

Compd. No.	Structure	Yield (%)	Compd. No.	Structure	Yield (%)
3a		84	3g		78
3b		91	3h		67
3c		90	3i		64
3d		84	3j		75
3e		86	3k		73
3f		75	3l		75

TABLE-2
 YIELD OF COMPOUNDS (6a-6e)

Compd. No.	Structure	Yield (%)
6a		72
6b		40
6c		80
6d		77
6e		72

Conclusion

In summary, an easy, catalyst free, efficient and environmentally friendly synthesis of imidazo[1,2-a]pyridines from 2-aminopyridines with α -bromo acyl derivatives is reported. The reactions are done in water as medium and at room temperature. Several products are isolated without any column chromatography with good to excellent yields. The drug like zolimidine has been synthesized using the developed procedure in high yield and purity using water as reaction medium.

ACKNOWLEDGEMENTS

Sincere thanks to Jubilant Chemsys Management in facilitating this research work and also to the analytical team for providing the spectral data.

REFERENCES

- N. Shapiro and A. Vigalok, *Angew. Chem.*, **120**, 2891 (2008); <https://doi.org/10.1002/ange.200705347>.
- (a) H.C. Hailes, *Org. Process Res. Dev.*, **11**, 114 (2007); <https://doi.org/10.1021/op060157x>.
(b) C.J. Li and T.H. Chan, in eds.: P.A. Grieco, *Organic Synthesis in Water*, Thomson Science: Glasgow: Scotland (1998).
(c) C.J. Li and T.H. Chan, *Organic Reactions in Aqueous Media*, Wiley: New York (1997).
(d) C.J. Li, *Chem. Rev.*, **105**, 3095 (2005); <https://doi.org/10.1021/cr030009u>.
- M. Adib, M. Mahdavi, M.A. Noghani and P. Mirzaei, *Tetrahedron Lett.*, **48**, 7263 (2007); <https://doi.org/10.1016/j.tetlet.2007.08.049>.
- A.S. Howard, in eds.: A.R. Katritzky, C.W. Rees and E.V.F. Scriven, *In Comprehensive Heterocyclic Chemistry*, Pergamon Press: London, vol. 8, Chap. 10, pp 262, and references therein (1996).
- F. Couty and G. Evano, in eds.: A.R. Katritzky, C.A. Ramsden, E.V.F. Scriven and J.K.R. Taylor, *In Comprehensive Heterocyclic Chemistry III*, Elsevier Science, Oxford, vol. 11, Chap. 10, pp. 409, and references therein (2008).
- (a) A.R. Katritzky, Y.J. Xu and H. Tu, *J. Org. Chem.*, **68**, 4935 (2003); <https://doi.org/10.1021/jo026797p>.
(b) S.Z. Langer, S. Arbilla, J. Benavides and B. Scatton, *Adv. Biochem. Psychopharmacol.*, **46**, 61 (1990).
(c) G.M. Carminati, *Farmaco Ed.*, **33**, 68 (1978).
- (d) J. Allen, G. Parent and A. Tizot, *J. Labelled Comp. Radiopharm.*, **23**, 807 (1986); <https://doi.org/10.1002/jlcr.2580230803>.
- (a) M. Adib, E. Sheikhi and N. Rezaei, *Tetrahedron Lett.*, **52**, 3191 (2011); <https://doi.org/10.1016/j.tetlet.2011.04.002>.
(b) A.B. Ramesha, G.M. Raghavendra, K.N. Nandeesh, K.S. Rangappa and K. Mantelingu, *Tetrahedron Lett.*, **54**, 95 (2013); <https://doi.org/10.1016/j.tetlet.2012.10.112>.
- (a) A.T. Khan, R. Sidick Basha and M. Lal, *Tetrahedron Lett.*, **53**, 2211 (2012); <https://doi.org/10.1016/j.tetlet.2012.02.078>.
(b) K. Groebke, L. Weber and F. Mehlin, *Synlett*, 661 (1998); <https://doi.org/10.1055/s-1998-1721>.
(c) C. Blackburn, *Tetrahedron Lett.*, **39**, 5469 (1998); [https://doi.org/10.1016/S0040-4039\(98\)01113-7](https://doi.org/10.1016/S0040-4039(98)01113-7).
(d) H. Bienayme and K. Bouzid, *Angew. Chem. Int. Ed.*, **37**, 2234 (1998); [https://doi.org/10.1002/\(SICI\)1521-3773\(19980904\)37:16<2234::AID-ANIE2234>3.0.CO;2-R](https://doi.org/10.1002/(SICI)1521-3773(19980904)37:16<2234::AID-ANIE2234>3.0.CO;2-R).
- (a) A. Gueiffier, S. Mavel, M. Lhassani, A. Elhakmaoui, R. Snoeck, G. Andrei, O. Chavignon, J.-C. Teulade, M. Witvrouw, J. Balzarini, E. De Clercq and J.-P. Chapat, *J. Med. Chem.*, **41**, 5108 (1998); <https://doi.org/10.1021/jm981051y>.
(b) J.E. Starrett, T.A. Montzka, A.R. Crosswell and R.L. Cavanagh, *J. Med. Chem.*, **32**, 2204 (1989); <https://doi.org/10.1021/jm00129a028>.
(c) A. Chaoui-Benabdallah, C. Galtier, H. Allouchi, A. Kherbeche, O. Chavignon, J.-C. Teulade, M. Witvrouw, C. Pannecouque, R. Snoeck, G. Andrei, J. Balzarini, E. De Clercq, F. Fauvel, C. Enguehard and A. Gueiffier, *Chem. Pharm. Bull. (Tokyo)*, **49**, 1631 (2001); <https://doi.org/10.1248/cpb.49.1631>.
- S. Mavel, J.-L. Renou, C. Galtier, H. Allouchi, R. Snoeck and G. Andrei, *Bioorg. Med. Chem.*, **10**, 941 (2002); [https://doi.org/10.1016/S0968-0896\(01\)00347-9](https://doi.org/10.1016/S0968-0896(01)00347-9).
- R.S. Varma and D. Kumar, *Tetrahedron Lett.*, **40**, 7665 (1999); [https://doi.org/10.1016/S0040-4039\(99\)01585-3](https://doi.org/10.1016/S0040-4039(99)01585-3).
- S.M. Ireland, H. Tye and M. Whittaker, *Tetrahedron Lett.*, **44**, 4369 (2003); [https://doi.org/10.1016/S0040-4039\(03\)00941-9](https://doi.org/10.1016/S0040-4039(03)00941-9).
- V.Z. Parchinsky, O. Shuvalova, O. Ushakova, D.V. Kravchenko and M. Krasavin, *Tetrahedron Lett.*, **47**, 947 (2006); <https://doi.org/10.1016/j.tetlet.2005.11.152>.
- A. Shaabani, E. Soleimani and A. Maleki, *Tetrahedron Lett.*, **47**, 3031 (2006); <https://doi.org/10.1016/j.tetlet.2006.03.011>.
- (a) L.R. Odell, M.T. Nilsson, J. Gising, O. Lagerlund, D. Muthas, A. Nordqvist, A. Karlen and M. Larhed, *Bioorg. Med. Chem. Lett.*, **19**, 4790 (2009); <https://doi.org/10.1016/j.bmcl.2009.06.045>.
(b) M.C. Pirrung, S. Ghorai and T.R. Ibarra-Rivera, *J. Org. Chem.*, **74**, 4110 (2009); <https://doi.org/10.1021/jo900414n>.
(c) S.K. Guchhait and C. Madaan, *Synlett*, 628 (2009); <https://doi.org/10.1055/s-0028-1087915>.
(d) M. Nayak, S. Kanajiya and S. Batra, *Synthesis*, 431 (2009); <https://doi.org/10.1055/s-0028-1083306>.
(e) A. Shaabani, E. Soleimani, A. Maleki and J. Moghimi-Rad, *Synth. Commun.*, **38**, 1090 (2008); <https://doi.org/10.1080/00397910701862931>.
(f) F. Mert-Balci, J. Conrad, U. Beifuss, K. Meindl, T. Schulz, D. Stalke and U. Beifuss, *Synthesis*, 3649 (2008); <https://doi.org/10.1055/s-0028-1083602>.
(g) A.L. Rousseau, P. Matlaba and C.J. Parkinson, *Tetrahedron Lett.*, **48**, 4079 (2007); <https://doi.org/10.1016/j.tetlet.2007.04.008>.
(h) A. Shaabani, A. Maleki, J. Moghimi-Rad and E. Soleimani, *Chem. Pharm. Bull. (Tokyo)*, **55**, 957 (2007); <https://doi.org/10.1248/cpb.55.957>.
(i) V.G. Nenajdenko, A.L. Reznichenko and E.S. Balenkova, *Russ. Chem. Bull.*, **56**, 560 (2007); <https://doi.org/10.1007/s11172-007-0093-1>.
- C. He, J. Hao, H. Xu, Y. Mo, H. Liu, J. Han and A. Lei, *Chem. Commun.*, **48**, 11073 (2012); <https://doi.org/10.1039/c2cc35927h>.
- Q. Cai, M.-C. Liu, B.-M. Mao, X. Xie, F.-C. Jia, Y.-P. Zhu and A.-X. Wu, *Chin. Chem. Lett.*, **26**, 881 (2015); <https://doi.org/10.1016/j.cclet.2014.12.016>.
- D.N. Kommi, P.S. Jadhavar, D. Kumar and A.K. Chakraborti, *Green Chem.*, **15**, 798 (2013); <https://doi.org/10.1039/c3gc37004f>.